Campagne de collecte 15 septembre 2024 – 1 octobre 2024 C'est quoi, la collecte de fonds?

Volume 23; Issue 1 Suppleme

Main
PharmacoEconomics
Volume 23; Issue 1 Suppleme

PharmacoEconomics

Volume 23; Issue 1 Suppleme

1

Cost effectiveness of long-acting risperidone: What can pharmacoeconomic models teach us?

Lieven Annemans

Journal:

PharmacoEconomics

Année:

2005

Langue:

english

Fichier:

PDF, 59 KB

english, 2005

2

Pharmacoeconomics of long-acting risperidone: Results and validity of cost-effectiveness models

Journal:

PharmacoEconomics

Année:

2005

Langue:

english

Fichier:

PDF, 157 KB

english, 2005

3

Modelling the treated course of schizophrenia: Development of a discrete event simulation model

Bart M. S. Heeg,Erik Buskens,Martin Knapp,Gerda van Aalst…

Journal:

PharmacoEconomics

Année:

2005

Langue:

english

Fichier:

PDF, 219 KB

english, 2005

4

Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

Diana De Graeve,Ann Smet,Angelika Mehnert,Sue Caleo…

Journal:

PharmacoEconomics

Année:

2005

Langue:

english

Fichier:

PDF, 157 KB

english, 2005

5

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

Gerd Laux,Bart M. S. Heeg,Ben A. van Hout,Angelika Mehnert

Journal:

PharmacoEconomics

Année:

2005

Langue:

english

Fichier:

PDF, 160 KB

english, 2005

6

Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada

P. S. Chue,Bart M. S. Heeg,Erik Buskens,Ben A. van Hout

Journal:

PharmacoEconomics

Année:

2005

Langue:

english

Fichier:

PDF, 152 KB

english, 2005

7

Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

Natalie Christine Edwards,Julie C. Locklear,Marcia F. T. Rupnow…

Journal:

PharmacoEconomics

Année:

2005

Langue:

english

Fichier:

PDF, 153 KB

english, 2005